Monopar Therapeutics (NASDAQ:MNPR) Given New $40.00 Price Target at HC Wainwright

Monopar Therapeutics (NASDAQ:MNPR) had its price target hoisted by HC Wainwright from $22.00 to $40.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also commented on the stock. Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $50.00 price target on the stock. Piper Sandler assumed coverage on Monopar Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating and a $72.00 target price on the stock.

Monopar Therapeutics Trading Up 6.3 %

Shares of NASDAQ MNPR opened at $33.67 on Wednesday. The company has a market cap of $205.39 million, a price-to-earnings ratio of -17.09 and a beta of 1.23. The stock’s 50 day simple moving average is $23.48 and its 200 day simple moving average is $12.00. Monopar Therapeutics has a 12-month low of $1.54 and a 12-month high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09. As a group, equities analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan purchased 1,550 shares of the company’s stock in a transaction on Monday, October 28th. The shares were purchased at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the transaction, the chief financial officer now owns 1,550 shares in the company, valued at $25,187.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 34.90% of the stock is currently owned by corporate insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.